Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of becatecarin versus 5-fluorouracil + leucovorin for advanced biliary tract tumors
2004-000327-15Phase 3Completed
- Sponsor
- Exelixis, Inc.
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of becatecarin in biliary cancer, gallbladder cancer and cholangiocarcinoma (CCA) (2 arms), sponsored by Exelixis, Inc. Primary endpoint: Overall survival. Started Nov 2004; status: completed.
02
Drugs
becatecarin
03
Conditions
biliary cancergallbladder cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2004-000327-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000327-15.